LQDA · Liquidia Corporation

Current Thesis

Liquidia Corporation’s recovery thesis requires continued YUTREPIA sales growth and a weekly close above the previously identified $70 shelf before a weekly close below $65 invalidates it. The operating benchmark is second-quarter 2026 YUTREPIA sales of $170.4 million, reported on 2026-08-12; the next quarterly report must exceed that figure for the commercial-growth case to progress. Liquidia’s second-quarter results.

The September event window has passed without recovery at the latest supplied endpoint: the adjusted close was $66.88 on 2026-09-18, compared with $68.66 on 2026-09-04. The 2026-09-08 Wells Fargo conference is now listed among past events. The earlier note’s expectation of recovery above $70 after the conference and respiratory congress has therefore not been met at this observation. Liquidia’s event calendar.

As an inference, the narrative is maturing — the commercial results published on 2026-08-12 remain the operating anchor, while the 2026-09-03 indication-expansion announcement has not produced a recovery above the published shelf by 2026-09-18. That classification would change with a weekly close above $70 accompanied by subsequent YUTREPIA sales above $170.4 million; the available price observations cannot establish whether participation has broadened or narrowed.

Bullish and bearish views on Liquidia Corporation

The model's bull view on Liquidia Corporation (LQDA), in brief: Commercial growth remains the anchor. Liquidia reported second-quarter 2026 YUTREPIA sales of $170.4 million, up 31% sequentially, on 2026-08-12. Sales at or below that amount in the next quarterly report would invalidate the sequential-growth leg. Company results. Indication… The bear view: The event-recovery condition remains unmet. Both cases follow in full.

Bull Case

• Commercial growth remains the anchor. Liquidia reported second-quarter 2026 YUTREPIA sales of $170.4 million, up 31% sequentially, on 2026-08-12. Sales at or below that amount in the next quarterly report would invalidate the sequential-growth leg. Company results.
• Indication expansion has a milestone. Liquidia’s 2026-09-03 announcement reported Food and Drug Administration Fast Track designation for Raynaud’s phenomenon associated with systemic sclerosis. It described RE-WARM as a Phase 2a study expected to begin in October 2026; initiation slipping beyond that month would invalidate the near-term execution claim. Company announcement.

Bear Case

• The event-recovery condition remains unmet. The supplied 2026-09-18 adjusted close of $66.88 remains below the $70 shelf identified in the 2026-09-05 published note, after the scheduled 2026-09-05–2026-09-09 congress window and 2026-09-08 conference. This establishes the endpoint, not the intervening daily path or the cause of weakness.
• Revenue concentration magnifies legal exposure. Liquidia’s 2026-08-12 release reported $170.4 million of YUTREPIA sales within $171.7 million of total second-quarter revenue. The 2026-05-11 quarterly filing warned that an adverse ’327 patent outcome could require removal of the pulmonary hypertension associated with interstitial lung disease indication, or potentially broader market removal; describing the maximum exposure as necessarily limited to one indication is too narrow. Company results, May quarterly filing.
• Clinical optionality remains early stage. The 2026-09-03 announcement describes RE-WARM as randomized, open-label and dose-finding, with primary completion targeted for February 2027. Those design and timing disclosures provide no completed efficacy result for the proposed indication. Company announcement.

Setup & Price Structure

The supplied adjusted series places the 2026-09-18 close at $66.88, 26.5% below its $91.03 52-week high, with a three-month price decline of 11.4%. The 14-period relative strength index was 47.6. That momentum reading does not itself establish a price base; no moving-average value or slope was supplied.

The $70 level is the July shelf identified in the 2026-09-05 public note. The $65 level retains that note’s published thesis boundary; it is not presented as newly measured technical support. The recovery case requires both a weekly close above $70 and next-quarter YUTREPIA sales above the reported $170.4 million benchmark before the downside condition fires.

Analyst coverage is observable, but investor crowding is not established. Stock Analysis’s table, updated 2026-09-09 and attributed to S&P Global and TipRanks, reports eight analysts, an average price target of $107.75 and a $90–$130 range. The different sample prevents treating this as a like-for-like increase from the earlier note’s consensus figure. No current retail-flow, short-interest or moving-average-distance measurement establishes crowded participation. Analyst table.

Catalyst Calendar (next 30 days)

• 2026-09-19–2026-10-19 — no confirmed day-specific company event. Liquidia’s event calendar lists no upcoming event at this review. The 2026-09-08 conference has elapsed and is not an upcoming catalyst. Company calendar.
• ~2026-11-02, estimated — third-quarter earnings. MarketBeat estimates this date and explicitly states that Liquidia has not confirmed it. This later event is included because sales above or below the second-quarter $170.4 million benchmark resolve the commercial-growth leg. Earnings calendar.

The ’327 litigation has no verified decision date in the reviewed material. The supplied 2026-08-12 call record described the ruling as pending; the absence of a later decision in the reviewed sources does not establish the current docket status.

Elapsed catalysts

• October 2026 — RE-WARM initiation window. The 2026-09-03 company announcement specifies October without a day, so initiation cannot be placed confidently inside the next 30 days. A company or registry confirmation of enrollment would establish execution; absence of initiation by the end of October would fail the stated timing. Company announcement. (passed 17d ago)

What Would Change Our Mind

Loss of the published downside boundary would end the recovery case: a weekly close below $65 breaches the level retained from the 2026-09-05 note. Separately, next-quarter YUTREPIA sales at or below $170.4 million would contradict the sequential-growth premise, while a court order restricting commercialization would break the assumption that the existing revenue engine remains available.

Positive confirmation requires a weekly close above the published $70 shelf together with YUTREPIA sales exceeding the 2026-08-12 reported benchmark in the next quarterly release. The 2026-09-18 close of $66.88 has not supplied that price confirmation. The low-conviction forecast concerns this defined recovery case, rather than the existence of an operating business or a clinical development program.

Correlation Notes

This remains a single-company setup: the supplied 2026-09-19 theme context assigns Liquidia to no active cluster. The 2026-08-12 revenue disclosure supports company-specific commercial exposure, and the May quarterly filing documents company-specific litigation exposure. Neither establishes a measured relationship with a biotechnology index or United Therapeutics shares; no paired return series was supplied, so a correlation claim is unsupported.